Search Bar & Filters
Found 3 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating a new medicine called NNC6019-0001 to see if it can reduce the risk of heart-related death and illness in people with transthyretin amyloid cardiomyopathy ATTR-CM, a condition that affects the heart. This phase 3 study compares NNC6019-0001 to a placebo, with participants continuing their regular heart treatments as advised by their doctors. The study aims to better understand cardiovascular outcomes in this patient group over time. Participants will receive either NNC6019-0001 or a placebo intravenously. Both groups may continue with their usual standard of care treatments as recommended by their healthcare providers. The treatment is given in a parallel design where each participant is randomly assigned to one of the two groups. The study will last up to approximately four years, allowing long-term observation of effects. During the study, participants will be regularly monitored through various assessments including questionnaires about heart health, walking tests, and measurements of heart function and biomarkers. Researchers will track cardiovascular deaths, hospital visits, and heart failure events among other outcomes. Safety and health status will be followed closely throughout the study period to evaluate the impact of the treatment compared to placebo.
Actively Recruiting
This research focuses on women aged 18 years or older who are hospitalized for their first episode of heart failure, regardless of their hearts ejection fraction. Women represent over half of heart failure hospital admissions but are often underrepresented in studies, especially concerning risk factors unique to women such as pregnancy complications and menopause timing. The study aims to describe the clinical and prognostic features of these women over a year and compare findings with a similar group of men to understand sex-specific differences better. Participants are enrolled at hospital discharge or within 15 days at a heart failure unit visit after their initial admission. The study does not assign treatments instead, all care decisions follow routine clinical practice. Women are followed for 12 months with visits scheduled at 3, 6, and 12 months. Data collected include detailed medical history, heart failure characteristics, treatments given, side effects, and social factors. Assessments include laboratory tests, heart imaging, and health status questionnaires. Throughout the study, participants undergo regular evaluations of their heart function, treatment tolerability, and overall health using standardized scales and questionnaires. Hospital visits and emergency care related to heart failure are tracked. Social and cognitive status, as well as quality of life, are assessed at the start and end of the study. The main outcome measured is whether participants experience death from any cause or worsening heart failure within 12 months. This comprehensive approach aims to improve understanding of heart failure in women.
Actively Recruiting
Researchers are evaluating the investigational drug omecamtiv mecarbil to see if it can reduce the risk of serious effects related to heart failure, such as hospitalization, heart transplantation, or death, in patients with symptomatic heart failure with severely reduced ejection fraction HFrEF. This Phase 3 trial compares the safety and effectiveness of omecamtiv mecarbil against a placebo in patients with this condition. Participants will be randomly assigned to receive either omecamtiv mecarbil or a placebo. Those in the omecamtiv mecarbil group will take oral tablets twice daily with doses adjusted based on drug levels in their blood 25, 37.5, or 50 mg. The treatment continues until at least 850 participants experience a heart failure event or cardiovascular death. This is a double-blind study, meaning neither participants nor study staff know who receives the drug or placebo. During the study, participants will be monitored up to about 3 years. Researchers will track occurrences of cardiovascular death, heart failure events, device implantations, heart transplants, and strokes. Participants will have regular visits and assessments to monitor their health and study outcomes. Safety and efficacy data will be collected until the study concludes when the required number of events has occurred.